The menopause gold rush is failing women — and what should replace it

Two things are true at the same time in 2026. Menopause has never been more visible, more funded, or more discussed. And most women in the menopausal transition still cannot get competent, guideline-based medical care from the health system they already pay for.

That gap is the business model. When mainstream medicine leaves a large, motivated, high-spending population underserved, a market fills the vacuum — telehealth clinics, influencer protocols, supplement lines, "hormone balancing" panels. Analysts describe women’s health as a ghost market worth hundreds of billions of dollars, with menopause one of its largest untended slices. The demand is real. The care it buys is wildly uneven.

Where the money actually goes

The clearest illustration is the supplement aisle. The global menopause supplement market is above $17 billion and growing more than 5% a year. Dietary supplements in the United States require no FDA pre-approval for safety or effectiveness, and no supplement has been shown to outperform placebo for hot flashes in rigorous trials. Meanwhile hormone therapy — the most effective treatment for moderate-to-severe vasomotor symptoms, and the one with the deepest evidence base — remains underused, two decades after the initial Women’s Health Initiative headlines were widely misread.

So the money flows toward the products with the weakest evidence and the loosest regulation, and away from the treatment with the strongest. That is not a consumer failure. It is a system failure that a market learned to monetize.

Why mainstream care did not keep up

• Menopause training is thin. Many clinicians completed residency with a few hours of menopause education and no framework for managing a decade-long transition.
• Guideline updates lagged. The main obstetric practice bulletin on menopause went more than a decade without substantial revision, and stayed focused narrowly on hot flashes and vaginal symptoms.
• Estrogen loss is multi-organ — bone, brain, muscle, and metabolism — but midlife care is still organized as if it were only a symptom checklist.
• Trust collapsed. Women aged 40 to 55 report low confidence that the health system will address their midlife needs, which pushes them toward self-advocacy, social media, and direct-to-consumer services.

The pattern is not unique to menopause

This is the same curve GLP-1 medications rode. Enormous unmet need, slow institutional response, a regulatory gray zone around compounding, and a two-tier outcome: women with resources get personalized, cutting-edge treatment, and women without get either nothing or a shelf of unproven products. We built a [state-by-state Medicaid coverage tracker](/glp1/medicaid-coverage-by-state) precisely because that divide is now measurable in state budget lines.

Peptides are in the early phase of the same arc: real mechanisms, thin long-term human data, and marketing that runs decades ahead of the evidence.

What an honest menopause service owes you

• Guideline concordance you can check. Named sources — The Menopause Society, ACOG, the Endocrine Society — not vibes. Ours are published on our [clinical governance page](/clinical-governance).
• Honesty about compounding. "Bioidentical" describes a molecule, not a risk profile. Compounded preparations are not FDA-tested for safety, effectiveness, or batch consistency, and an FDA-approved product should be the default when one fits. Our [compounded HRT policy](/compounded-hrt-policy) says exactly when we deviate and why.
• Revenue that does not depend on selling you pills with no evidence. If a clinic’s margin comes from supplements, its incentives are pointed away from you.
• Measured outcomes, published. Validated symptom scores, metabolic markers, adherence, discontinuation, adverse events — reported in aggregate, including the unflattering parts.

What we are doing about it

Kindr sits inside this market, which means the critique applies to us too. Our answer is to make the standards checkable rather than asserted: published guideline sources, a published compounding policy, a six-month protocol review cycle, a public list of treatments we refuse to prescribe (pellets among them), and a commitment to publish an annual aggregate outcomes report.

We also restructured our plans around clinical complexity instead of product count: Core for guideline-concordant hormone therapy, Plus for hormone therapy coordinated with metabolic treatment, and Complex for women whose history — prior cancer, clotting risk, complex psychiatric history — needs closer oversight rather than a polite refusal.

None of that is charity. Evidence-first care is simply the only version of this business that survives contact with the next decade of data. The gold rush will end. What should be left behind is the infrastructure that ought to have existed all along.

Medically reviewed by Kindr Health Clinical Team
Kindr Health Inc. — Editorial & Clinical Team (physician-supervised)
NPI 1609792902 · Last reviewed: July 3, 2026